Select a community
Mood Conditions including Depression, Anxiety, Bipolar, OCD, and PTSD
Find out more about the PatientsLikeMe
Mood Conditions Community
Home > Community Treatment Reports > Rozerem Treatment Report
What is Rozerem?

Rozerem is a brand name for the drug Ramelton, a melatoninergic prescription sleep aid used in the treatment of insomnia. Read more...Click to read more below

Takeda Pharmaceuticals's Rozerem site

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Insomnia 12 5
Other 3 0
getting to sleep 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
1 20%
Mild
0 0%
None
4 80%

Most commonly reported side effects

can't get to sleep
1 20%
feeling drugged
1 20%
  • Mild
  • Moderate
  • Severe

Dosages

  2 8mg as needed 8 mg daily
  1 Number of Patients: 1 6 Number of Patients: 6  

Stop Reasons

Why Patients Stopped Taking Rozerem (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work
7 58% Did not seem to work: 58%
Side effects too severe
3 25% Side effects too severe: 25%
Other
2 17% Other: 17%
Course of treatment ended
2 17% Course of treatment ended: 17%
Expense
1 8% Expense: 8%
Doctor's advice
1 8% Doctor's advice: 8%

See all 12 patients who’ve stopped taking Rozerem

Currently Taking Rozerem

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
1
0
1
2
0

Stopped Taking Rozerem

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
4
4
1
1
2
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
2 40%
Usually
1 20%
Sometimes
1 20%
Never
1 20%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
1 20%
Not at all
4 80%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
1 20%
< $25
1 20%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 21, 2009.